All In Biotech

Free tool

Medicare drug spending

CMS's Spending by Drug data: what Medicare paid for each drug before manufacturer rebates. Part D covers drugs dispensed by pharmacies; Part B covers drugs given in a doctor's office or hospital outpatient department. Commercial and list prices are not public data and are not shown.

Last checked: Nov 20, 2026Latest source record: 2024 calendar yearSource: CMS (Medicare Part D Spending by Drug : 2024-01-01; Medicare Part B Spending by Drug : 2024-01-01)Methods & limitations

Part D, 2024

$288.7B

Gross drug spending in the dataset

Part B, 2024

$60.8B

Gross drug spending in the dataset

Drugs listed

5

Part D and Part B

Total spending by year

  • Part D
  • Part B
View as table
YearPart DPart B
2020$194,092,038,339$37,778,829,680
2021$213,513,349,361$40,135,340,775
2022$239,779,215,689$44,241,259,745
2023$275,808,918,753$50,775,853,083
2024$288,667,842,058$60,838,164,403
Reset

Top 5 by total spending

2024 figures. Growth compares with 2023. Per-beneficiary ranks skip drugs with fewer than 11 beneficiaries.

DrugPartSpendingChangeBeneficiariesPer beneficiaryPer unit
Reclast*

Zoledronic Acid/Mannitol-Water* · J3489

B$4.2M-21%96,550$43$6.48
Zoledronic Acid

Zoledronic Acid/Mannitol-Water

D$1.6M-14%10,061$156$1.54
Zoledronic Acid

Zoledronic Acid

D$438K-44%1,238$354$21.58
Reclast

Zoledronic Acid/Mannitol-Water

D$106K+24%104$1,015$10.05
Zoledronic Acid

Zoledronic Ac/Mannitol/0.9nacl

D$86K+18%204$422$1.48

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.